PTSM: Pharmaceutical Technology Sourcing and Management, Nov 7, 2012 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

PTSM: Pharmaceutical Technology Sourcing and Management, Nov 7, 2012
Global Feature
Contract Manufacturers and Fine-Chemicals Producers Expand
By Patricia Van Arnum
Fine-chemical manufacturers producers and contract manufacturers announce manufacturing and service expansions at CPhI in Madrid.
Biologics
Mixed Reviews for Biotechnology Financing
By Patricia Van Arnum
Venture-capital funding is up, but initial public offerings still are weak.
Outsourcing
Sizing the Market For Contract Manufacturing
By Jim Miller
Measuring the size of the market for contract manufacturing services requires a careful hand.
Formulation, Manufacturing
Seeking Solutions in Solid-State Chemistry
By Patricia Van Arnum
Particle-engineering technologies, such as crystal design for crystallization and producting cocrystals, particle-size reduction, and amorphous solid dispersions, help to optimize delivery of a drug.
CSR and Sustainability Forum
CSR and Sustainability in the News
A roundup of developments in corporate social responsibility (CSR) and sustainability from the bio/pharmaceutical industry, its suppliers, and other public and private organizations.
Eli Lilly, Merck Serono, and Astellas Call for Innovation in Global Health
By Patricia Van Arnum
Pharmaceutical companies and public health officials gather at the IFPMA Assembly to urge for greater innovation and private and public partnerships to address global health concerns.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
Click here